An open-label, multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in adult patients with newly diagnosed Fms-like tyrosine kinase receptor (FLT3) mutated Acute Myeloid Leukemia (AML) who are eligible for standard induction and consolidat

Project: Research project

Project Details

StatusFinished
Effective start/end date3/22/16 → 6/30/18

Funding

  • Novartis Pharmaceuticals Corporation ( Award # ): $8,000.00